HPV Polyepitope Constructs for Broad Genotype Immune Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines are ineffective for women with existing HPV infections and have limited coverage against less prevalent oncogenic genotypes, and existing treatments for HPV infections are unsatisfactory due to persistent virus persistence and recurrence of disease.
Innovation Solution
Development of polyepitope constructs targeting HPV16, 18, 31, and 45 genotypes, including CTL and HTL epitopes from E1, E2, E4, E5, E6, and E7 proteins, to induce a broad and potent immune response, preventing and treating HPV infections at various stages, including precancerous stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional HPV vaccines targeting only HPV16 and HPV18 are used, then coverage against the most prevalent oncogenic genotypes is achieved, but coverage against less prevalent oncogenic genotypes (such as HPV31 and HPV45) is insufficient
Solution Approach 1:
The vaccine is segmented into multiple polyepitope constructs, each targeting specific HPV genotypes (HPV16/18, HPV31, HPV45). Each construct contains carefully selected CTL and HTL epitopes from viral proteins, allowing targeted immune response against different genotype segments while maintaining manageable composition complexity
Solution Approach 2:
The vaccine employs universal T-cell epitopes that can recognize and respond to multiple HPV genotypes. By selecting epitopes conserved across genotype families and using both CTL and HTL epitopes, the vaccine achieves multi-functional coverage against prevalent, intermediate, and less prevalent oncogenic genotypes through a single immunization formulation
2Reliability
If prophylactic vaccines are administered before sexual debut, then prevention of initial HPV infection is achieved, but treatment of existing HPV infections and persistent infections is not provided
Solution Approach 1:
The vaccine formulation changes the immune response parameters by including both CTL (cytotoxic T lymphocyte) and HTL (helper T lymphocyte) epitopes in specific ratios and combinations. This dual-component approach enables the vaccine to function both prophylactically (inducing strong initial immune response) and therapeutically (boosting existing immune response against persistent infections), adapting to different infection stages through immunological mechanism modulation
3Ease of operation
If treatments focus on clearing visible warts, then clinical symptoms are removed, but elimination of the virus is not achieved and recurrence is common
Solution Approach 1:
The treatment extracts and targets the fundamental cause (viral persistence) rather than just the visible symptom (warts). By using polyepitope constructs that target conserved viral proteins and induce strong cellular immune responses, the treatment eliminates the virus itself, preventing recurrence while maintaining operational simplicity through single-agent immunotherapy
4Productivity
If vaccine targets only prevalent HPV genotypes, then immediate impact on major cancer cases is achieved, but less prevalent oncogenic genotypes will take over and cause disease
Solution Approach 1:
The vaccine takes preliminary action by providing broad-spectrum coverage against multiple genotype families (HPV16, HPV18, HPV31, HPV45) simultaneously. By pre-positioning immune recognition capabilities against both prevalent and less prevalent genotypes, the vaccine prevents genotype replacement before it can occur, maintaining long-term protection while delivering immediate impact on major cancer cases
Data Source
AI summary
The present invention is directed to HPV polyepitope construct and the use thereof for the prevention and/or treatment of HPV infection.